https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-29 / Oncoimmunology 2018;7(4):e1412901
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-29 / Oncoimmunology 2018;7(4):e14129012018-01-29 00:00:002019-02-15 08:47:40Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8 T cell activation in the presence of adjuvant temozolomide
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-26 / J Clin Oncol 36, 2018 (suppl 5S; abstr 96)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-26 / J Clin Oncol 36, 2018 (suppl 5S; abstr 96)2018-01-26 11:47:012021-05-19 14:28:45Autologous tumor lysate-pulsed dendritic cell vaccination therapy after resection of stage IIA (T2N0, T3N0) esophageal cancer: An analysis of immunological responses.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-25 / J Clin Oncol 36, 2018 (suppl 5S; abstr TPS201)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-25 / J Clin Oncol 36, 2018 (suppl 5S; abstr TPS201)2018-01-25 11:36:152019-07-17 11:37:00A prospective, randomized, blinded, placebo-controlled, phase IIb trial of an autologous tumor lysate + yeast cell wall particles (YCWP) + dendritic cells (DC) vaccine vs unloaded YCWP + DC and embedded phase I/IIa trial with tumor lysate particle only (TLPO) vaccine in stage III and stage IV (resected) melanoma to prevent recurrence.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-10 / Oncotarget 2018 Feb;9(11):10110-10117
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-10 / Oncotarget 2018 Feb;9(11):10110-101172018-01-10 00:00:002018-01-10 00:00:00A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-03 / PLoS ONE 2018;13(1):e0190638
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-03 / PLoS ONE 2018;13(1):e01906382018-01-03 00:00:002020-01-08 10:08:47EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-12-21 / BMC Cancer 2017 12;17(1):884
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-12-21 / BMC Cancer 2017 12;17(1):8842017-12-21 00:00:002019-02-15 08:45:44Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-12-12 / Clin. Cancer Res. 2018 Feb;24(4):766-776
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-12-12 / Clin. Cancer Res. 2018 Feb;24(4):766-7762017-12-12 00:00:002019-02-15 08:50:39Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-12-05 / J. Neurol. 2018 Apr;265(4):741-756
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-12-05 / J. Neurol. 2018 Apr;265(4):741-7562017-12-05 00:00:002019-02-15 08:47:38Advances in immunotherapeutic research for glioma therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-11-23 / Melanoma Manag 2017 Dec;4(4):203-215
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-11-23 / Melanoma Manag 2017 Dec;4(4):203-2152017-11-23 00:00:002017-11-23 00:00:00An update on the relevance of vaccine research for the treatment of metastatic melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-11-01 / Cancer Immunol. Immunother. 2018 02;67(2):285-298
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-11-01 / Cancer Immunol. Immunother. 2018 02;67(2):285-2982017-11-01 00:00:002019-02-15 08:49:51A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients
